One article clarifies it all: Are Zhongyi Life’s participating insurance policies really worth buying?

Moreover, Zhongyi Life does not chase outsized profits during bull markets; instead, it excels at resisting downturns during bear markets. In 2022, the industry’s average investment return dropped to 3.76%, with many insurers falling below 3%—yet Zhongyi Life held steady at 4.02%. From 2023 to 2025, as the industry’s returns continued declining to below 3.5%, Zhongyi Life consistently maintained a stable range of 3.7%–3.9%. Under new regulatory rules effective in 2025, the maximum illustrated dividend rate for participating insurance policies may not exceed the insurer’s average financial investment return over the prior three years—and is capped at 3.2%. By contrast, Zhongyi Life’s average return from 2023 to 2025 reached 4.71%, significantly surpassing the regulatory cap and leaving ample profit margin to fulfill its dividend commitments. Zhongyi Life’s ability to achieve this stems from two key advantages: ① Exclusive national-level infrastructure investment resources Leveraging its shareholder background—China National Petroleum Corporation (CNPC)—Zhongyi Asset Management has deep involvement in nationally significant infrastructure projects inaccessible to other insurers: ・West-East Gas Pipeline Project: A RMB 36-billion equity investment program—one of China’s largest energy infrastructure initiatives. ・CNPC Western Pipeline Project: Another RMB 36-billion equity investment program. ・Beijing–Shanghai High-Speed Railway: China’s most profitable railway line, serving over 1 billion passengers annually. ・Shandong Expressway, Chengdu–Europe Express Railway, and other transportation infrastructure projects. These projects feature long tenors, stable returns, and low risk—perfectly matching the long-term capital requirements of participating insurance policies. ② Mature, prudent asset management capability and risk control system Zhongyi Life owns a wholly owned asset management subsidiary—Zhongyi Asset Management—one of China’s earliest-established insurance asset managers, managing over RMB 500 billion in assets. Zhongyi Asset employs a dual-barbell portfolio structure—“Core Portfolio + Satellite Portfolio”—for asset allocation: ・Core Portfolio (over 80% of total): Comprised mainly of long-duration interest-rate bonds, high-dividend-quality equities, and infrastructure projects—delivering stable base returns. ・Satellite Portfolio (under 20%): Allocates modestly to equity and alternative assets to enhance return elasticity. Additionally, the foreign shareholder—Generali Group—brings nearly 200 years of global investment experience and a robust risk-control framework, providing Zhongyi Asset with strong technical support. This enables Zhongyi Life to pursue returns while effectively containing risk—avoiding dramatic swings in investment performance. In short, Zhongyi Life’s investment capability is not that of a speculative “get-rich-quick” operator, but rather a long-termist, cycle-resilient capability—the very trait most essential for participating insurance. After all, buyers of participating insurance don’t seek overnight wealth—they seek money reliably delivered decades later. Beyond Zhongyi Life, I’ve also compared the 10-year investment returns of 90 insurers. If you’d like this data, click the card below and add me to receive it free of charge. III. Is Zhongyi Life willing to share dividends with customers? A strong shareholder background and solid operational capacity indicate promising growth prospects—but for participating insurance buyers, one critical question remains: When the insurer earns profits, will it truly share them with policyholders? Dividend payout ratios serve as a litmus test for an insurer’s willingness to distribute dividends—that is, whether its promises hold up in practice. Zhongyi Life stands out among very few insurers in the industry by publicly disclosing the annual dividend payout ratio for every single product over the past 20 years.

Are there cost-effective alternatives to Ecolab cleaning agents? These affordable options are worth attention.

Are there cost-effective alternatives to Ecolab cleaning agents? These affordable options are worth attention. As a global leader in hygiene solutions, Ecolab is virtually ubiquitous in food manufacturing plants, central kitchens, and commercial back-of-house operations. Its product portfolio covers cleaning, disinfection, and CIP (Clean-in-Place) pipeline treatment—and holds multiple international certifications including FDA and NSF, ensuring reliable quality. Yet a challenge arises: Ecolab’s pricing model targets large multinational corporations or premium-chain operators. For small-to-medium food processors, regional F&B brands, and independent vendors, annual spending on cleaning agents often constitutes a substantial burden. So, are there alternatives that meet food-grade safety standards *while* meaningfully lowering costs? This article avoids generic “Top 10 Brands” lists. Instead, it conducts a practical, horizontal comparison grounded in real-world usage scenarios—focusing squarely on value-for-money, regulatory compliance, and operational stability. ———————————————————————— Affordable international alternatives: When Ecolab is no longer the only option First, consider overseas brands. Diversey—a veteran player in food-industry cleaning and disinfection—has earned solid reputations for its low-foaming alkaline cleaners in breweries and dairy production lines. Some of its products retail at 15%–20% lower than comparable Ecolab offerings. However, Diversey’s distribution network in China remains relatively narrow; smaller clients rarely access factory-direct pricing, and logistics plus service overhead erode much of the theoretical price advantage. Novozymes specializes in enzymatic technology. Its enzyme-based cleaners efficiently break down grease and protein residues—even under low-temperature, low-alkalinity conditions—making them ideal for environmentally rated facilities. Yet enzymes demand strict storage conditions and temperature control; improper handling easily leads to deactivation, raising daily operational costs. Moreover, if a facility’s existing cleaning protocol relies heavily on alkaline foam systems, switching abruptly to enzymatic cleaning may disrupt established workflows. Kao and 3M offer food-grade product lines well-known in the consumer goods sector—but in industrial bulk packaging (e.g., 20L, 200L, or ton containers) and custom-formulation services, they typically serve only as supplementary options—not primary replacements. The reason is straightforward: end-user pricing, combined with distributor markups, often renders their total landed cost no cheaper than Ecolab’s. Overall, genuinely “same-quality, lower-price” international alternatives remain scarce. In most cases, breakthroughs in value-for-money come from domestic professional manufacturers. ———————————————————————— Domestic professional brands: High-value options backed by mature supply chains Over the past two decades, China’s food-grade cleaning and disinfection industry has nurtured several reputable manufacturers holding production licenses issued by the National Medical Products Administration (NMPA) or health authorities—and certified compliant with China’s national standards for food-contact materials. Their products match imported brands in safety, yet avoid multi-tiered distribution markups and brand premiums. As a result, invoice prices commonly run 30%–50% lower than Ecolab’s. Shanghai Jiameng Industrial Co., Ltd. is one such brand worthy of close attention. Founded in 1994, Jiameng has long specialized in food-industry cleaning and disinfection. Its comprehensive product line includes alkaline foam cleaners, CIP pipeline cleaners, and food-grade disinfectants—covering full-cycle sanitation needs.

Fideuram Intesa Sanpaolo Invests $7.14 Million in Ecolab Inc.

May 20, 2026

Fideuram Intesa Sanpaolo acquired 27,191 shares worth $7.14 million in Ecolab during Q4. Ecolab reported Q1 earnings matching expectations and declared a quarterly dividend of $0.73 per share.

MarketBeat

2026-04-13

Mar Vista Investment Partners Initiates New Position in Ecolab Inc.

2026-04-23

M&T Bank Corp Acquires 422,471 Shares of Ecolab Inc.

2026-04-25

Impax Asset Management Increases Stake in Ecolab Inc.

2026-04-27

Vanguard Group Inc. Acquires 137,578 Shares of Ecolab Inc. $ECL

2026-04-28

Stifel reiterates Ecolab stock rating on mixed quarterly results